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http://dx.doi.org/10.1016/j.ccr.2013.06.002SUMMARYThe prosurvival protein BCL-2 is frequently overexpressed in estrogen receptor (ER)-positive breast cancer.
We have generated ER-positive primary breast tumor xenografts that recapitulate the primary tumors and
demonstrate that the BH3 mimetic ABT-737 markedly improves tumor response to the antiestrogen tamox-
ifen. Despite abundant BCL-XL expression, similar efficacy was observed with the BCL-2 selective inhibitor
ABT-199, revealing that BCL-2 is a crucial target. Unexpectedly, BH3 mimetics were found to counteract the
side effect of tamoxifen-induced endometrial hyperplasia. Moreover, BH3 mimetics synergized with phos-
phatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors in eliciting apoptosis.
Importantly, these two classes of inhibitor further enhanced tumor response in combination therapy with
tamoxifen. Collectively, our findings provide a rationale for the clinical evaluation of BH3 mimetics in therapy
for breast cancer.INTRODUCTION
Impairment of apoptosis is a hallmark of cancer, playing a key
role in resistance to anticancer therapy. Tumors deploy diverse
strategies to limit or evade apoptosis that frequently involveSignificance
Endocrine therapy remains the standard of care for ER-positiv
B subtype, many patients also require chemotherapy. Here, w
significant benefit above tamoxifen alone for luminal B tumors
the BH3 mimetic. Moreover, synergy between the BH3 mimet
could be exploited in triple therapy with tamoxifen. PI3K/mT
of BAD to promote apoptosis and synergize with the BH3 mime
studies of ABT-199 in breast cancer, utilizing BCL-2 as a com
120 Cancer Cell 24, 120–129, July 8, 2013 ª2013 Elsevier Inc.perturbation of the BCL-2 intrinsic apoptotic pathway (Strasser
et al., 2011). Notably, the fate of tumor cells exposed to anti-
cancer therapy may reflect their proximity to an apoptotic
threshold (Ni Chonghaile et al., 2011). In this context, elevated
levels of prosurvival proteins, such as BCL-2, bound toe breast cancer. Due to the poorer prognosis of the luminal
e demonstrate that concomitant targeting of BCL-2 confers
, likely due to acute disruption of BCL-2/BIM complexes by
ic and a PI3K/mTOR inhibitor in the induction of apoptosis
OR inhibition increased the active, dephosphorylated form
tic. These results provide a rationale for early-phase clinical
panion biomarker.
Figure 1. BCL-2 and BCL-XL Expression
in Breast Cancer and Primary Xenograft
Tumors
(A) Box-plots of BCL2 and BCL2L1 expression in
breast tumor subtypes.
(B) Immunostaining for ER, PR, BCL-2, and Ki-67
expression in passage 2 breast tumor xenografts
23T, 315T, 50T, and 838T. Percent Ki-67 scores
were 33% ± 3%, 37% ± 3%, 63% ± 3%, and
47% ± 9%, respectively (mean ± SEM of three
tumors). Inset: BCL-2 control (no primary anti-
body). Scale bar, 50 mm.
(C) Western blot analysis of ER, BCL-2, MCL-1,
BCL-XL, BIM, NOXA, PUMA, p53, AKT, pAKT, and
PI3K expression in tumor xenografts. Actin was
used as a loading control.
See also Figure S1 and Table S1.
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BCL-2 Inhibition in Breast Cancerproapoptotic family members, such as BIM, may prime tumor
cells for apoptosis following chemotherapy.
BCL2 is an estrogen-responsive gene, and its protein product
BCL-2 is overexpressed in about 85%of estrogen receptor (ER)-
positive breast cancer (Dawson et al., 2010). While BCL-2 has
emerged as an important prognostic marker in breast cancer,
its precise role as a predictive marker or therapeutic target is
not known (Lindeman and Visvader, 2013). Currently, tamoxifen
or aromatase inhibitors are the mainstay of therapy for ER-
positive breast cancer. Since the luminal B subset of ER-positive
breast cancer is characterized by increased Ki-67 and is asso-
ciated with a poorer prognosis, chemotherapy is often also
required (Goldhirsch et al., 2011), albeit in an untargetedmanner.
Therefore, more effective therapeutic strategies are critically
needed for this common subtype of breast cancer.
BH3 mimetics are small-molecule inhibitors that mimic the
action of proapoptotic ‘‘BH3-only’’ proteins, thereby counteract-
ing prosurvival proteins, such as BCL-2 (Davids and Letai, 2012).
The BH3 mimetic ABT-737 and its orally bioavailable analog
ABT-263 (navitoclax) neutralize the prosurvival proteins BCL-2,
BCL-XL, and BCL-W but not MCL-1 or A1 (Oltersdorf et al.,
2005; Tse et al., 2008) and have demonstrated efficacy in breast
cancer cell lines (Chen et al., 2011) and triple negative breast
tumor xenografts when combined with cytotoxic therapy (Oakes
et al., 2012). Analysis of these breast tumor xenografts sug-
gested that BCL-2 was the likely target of ABT-737. Pertinently,
a potent BCL-2-selective inhibitor ABT-199 has recently been
developed (Souers et al., 2013). ABT-199 is platelet-sparingCancer Cell 24, 120(Souers et al., 2013; Vandenberg and
Cory, 2013), unlike ABT-737 or ABT-
263, both of which induce thrombo-
cytopenia due to their neutralization of
BCL-XL in platelets (Mason et al., 2007).
Indeed, clinically significant thrombocy-
topenia (and neutropenia) were observed
in a phase I study of ABT-263 in com-
bination with docetaxel in solid tumors
(Puglisi et al., 2011). ABT-199 was
recently shown to elicit promising tumor
responses in BCL-2-dependent hemato-
poietic malignancies (Davids and Letai,2013; Green and Walczak, 2013), but its in vivo potency for solid
tumors is not known. In this study, we have investigated a po-
tential role for ABT-737 and ABT-199 in endocrine-responsive
breast cancer.
RESULTS
To examine the expression of BCL2 and BCL2L1, which
encodes BCL-XL, across the different subtypes of breast can-
cer, we interrogated a large gene expression data set that
covers almost 2,000 breast cancers (Curtis et al., 2012). BCL2
was prominently expressed in the luminal subtypes, which are
primarily characterized by ER expression (Figure 1A, left panel).
Slightly higher levels of BCL2were observed in luminal A relative
to luminal B tumors (fold change 1.11; p < 0.0015), while signif-
icantly lower levels were evident in basal-like and human
epidermal growth factor receptor 2 (HER2)-positive tumors.
For example, BCL2was 2.5-fold upregulated in luminal B versus
basal-like tumors (p < 1016). Conversely, BCL2L1 appeared to
be more uniformly expressed among all tumor subtypes (Fig-
ure 1A, right panel), with a 1.3-fold difference noted between
luminal B and basal-like cancers (p < 1016). Overall, these find-
ings suggested that BCL-2 and BCL-XL could serve as potential
therapeutic targets in ER-positive breast cancer.
We generated an extensive bank of breast tumor xenografts
that include ER-positive, HER2-positive, and triple negative
tumors, which lack ER, progesterone receptor (PR), and
HER2 expression. These were derived through orthotopic–129, July 8, 2013 ª2013 Elsevier Inc. 121
Table 1. Engraftment of Primary Breast Tumors According to
Tumor Phenotype
Tumor Subtype Take Rate (%)a
Triple negative 17/28 (60.7)
Luminal
ER+ PR+ or  13/108 (12.0)
ER PR+ 2/8 (25.0)
HER2-positive 5/14 (35.7)
Total 37/158 (23.4)
aTake rate represents the number of primary tumors that were success-
fully established as xenografts in recipient animals and proved capable of
further passage.
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BCL-2 Inhibition in Breast Cancertransplantation of primary breast tumor tissue into the inguinal
mammary fat pads of immunocompromised nonobese diabetic
(NOD)-severe combined immunodeficiency (SCID)-interleukin-2
receptor common gamma chain (IL2Rgc)
/ mice. Such models
offer significant advantages over cell line-based xenografts, as
they recapitulate features of the primary tumor (DeRose et al.,
2011; Landis et al., 2013). Although triple negative and HER2-
positive tumors engrafted more readily, several ER-positive
tumors were successfully passaged (Table 1).
To evaluate BCL-2 as a therapeutic target in ER-positive
breast cancer, we selected three ER-positive xenograft models
(23T, 315T, and 50T) and one ER-negative model (838T) (Oakes
et al., 2012) for analysis (Figures 1B and 1C; Table S1 available
online). Tumor morphology and immunohistochemical staining
of these xenografts recapitulated that of the primary tumor
(Table S1). Based on Ki-67 expression in the primary breast
tumors and their derivative xenografts, as well as gene profiling
(Figure S1), these ER-positive tumors corresponded to the
luminal B subtype. All four models also expressed abundant
BCL-2 (Figures 1B and 1C), with divergent levels of other
BCL-2 family members. As expected, high levels of BCL-XL
were present in all the ER-positive tumors (Figure 1C).
To address whether ABT-737 could enhance responsiveness
to tamoxifen in ER-positive cancers, four xenograft models
were subjected to therapy with single or double agents (Figures
2A and S2A). Slow-release tamoxifen pellets were implanted
subcutaneously into cohorts of mice bearing xenograft tumors,
and mice were treated with ABT-737 or vehicle control on days
1–10 in two 21 day cycles. In all four xenograft models, ABT-
737 alone elicited minimal response. However, when adminis-
tered in combination with tamoxifen, ABT-737 significantly
attenuated tumor progression in all three ER-positive tumor
models compared to tamoxifen alone. As anticipated, combina-
tion therapy had little effect on the ER-negative 838T xenograft.
Complete tumor regression was observed in all mice bearing 23T
xenografts, accompanied by the re-emergence of stromal adi-
pocytes. In contrast, only a partial, unsustained response was
achieved in mice treated with tamoxifen alone (Figures S2A
and S2B). Thus, the combination of ABT-737 with tamoxifen
improved tumor response and prolonged survival.
To gain mechanistic insight into the response to combination
therapy, mice bearing 23T tumors were subjected to a brief
10 day treatment with ABT-737 and tamoxifen, which led to a
marked reduction in tumor burden (Figure S2C). Consistent122 Cancer Cell 24, 120–129, July 8, 2013 ª2013 Elsevier Inc.with the tumor response, apoptotic foci determined by cleaved
caspase-3 immunostaining were significantly increased in
tumors treatedwith combination therapy compared to tamoxifen
alone (Figure 2B). Combined therapy also profoundly curtailed
tumor proliferation, similar to that observed with tamoxifen alone
(Figure 2C).
Since increased BCL-2/BIM complexes appear to sensitize
tumors to ABT-737-induced cell death (Del Gaizo Moore et al.,
2007; Me´rino et al., 2012), the augmented apoptotic response
evident here is likely to reflect the increase in both BCL-2 and
BIM by tamoxifen treatment (Figure 3A). As expected, ABT-737
readily disrupted BCL-2/BIM complexes either in the presence
or absence of tamoxifen (Figures 3B, S3A, and S3B). To deter-
mine whether BCL-2 was a central mediator of responsiveness,
the BCL-2-selective inhibitor ABT-199 was next tested on 23T,
315T, and 50T xenografts cultured in vitro as nonadherent tumor
spheres. These were treated with tamoxifen alone or in com-
bination with ABT-737 or ABT-199 (Figure 3C). While tamoxifen
elicited apoptosis, a more profound effect was observed in
combination therapy with either ABT-737 or ABT-199. Notably,
ABT-199 was just as effective as ABT-737 in this in vitro assay,
despite its specificity for BCL-2.
We next examined the in vivo efficacy of ABT-199 or ABT-737
combined with tamoxifen using the 23T, 315T, and 50T xeno-
grafts models (Figures 3D and S3C). ABT-199 was administered
on days 1–5 and 8–12 by oral gavage in 21 day treatment cycles
to mimic ABT-737 treatment. Compatible with in vitro findings,
ABT-199 or ABT-737 in combination with tamoxifen was equally
effective at inducing a tumor response, despite abundant BCL-
XL expression (Figure 1C). Indeed, ABT-199 and tamoxifen
induced rapid and complete tumor regression in the 23T model,
comparable to ABT-737 plus tamoxifen (Figure 3D, left panel).
Only a partial, unsustained response was observed with tamox-
ifen alone. In the 315T and 50T models, combination therapy
with tamoxifen and ABT-737 or ABT-199 were equally effective
in delaying tumor growth (Figure 3D, middle and right panels,
and S3C), while no tumor response was elicited using ABT-199
alone at this dose (data not shown). Thus, BCL-2 appears to
be a crucial in vivo target in breast tumors that express both
BCL-XL and BCL-2, which are frequently coexpressed in breast
cancer (Oakes et al., 2012). Importantly, combination therapy
appeared to be well tolerated, with mice maintaining normal
body weight (data not shown). Since NOD-SCID-IL2Rgc
/
mice have profound leukocyte defects, we performed hemato-
logic analysis on immunocompetent FVB/JN mice treated with
combination therapy. As anticipated, platelets were spared by
ABT-199 (Souers et al., 2013; Vandenberg and Cory, 2013),
whereas ABT-737 elicited thrombocytopenia, due to its neutral-
ization of BCL-XL in platelets (Mason et al., 2007; Table S2).
Other hematopoietic parameters were not affected by concom-
itant tamoxifen therapy.
Given that endometrial hyperplasia and cancer are recognized
side effects of tamoxifen (due to its proestrogenic activity on
endometrium), we next examined the uteri of mice treated
with combination therapy. Unexpectedly, the uteri of ABT-
737-treated mice appeared significantly smaller than their
counterpart vehicle- or tamoxifen-treated controls (Figure 4A).
Histological examination of transverse sections of uterine
ducts revealed that the simple hyperplasia observed 10 days
(legend on next page)
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concomitant therapy with ABT-737, as determined by reduced
endometrial thickness and complexity (Figure 4B). ABT-199
alone did not appear to reduce endometrial diameter (Figure 4C).
Tamoxifen-induced endometrial proliferation was accompanied
by profound apoptotic activity in the presence of the BH3
mimetic, with cleaved caspase-3-positive cells being shed into
the endometrial lumina (Figure 4D). Together, these findings
raise the possibility that BH3 mimetic therapy may alleviate
tamoxifen-induced endometrial hyperplasia.
Interestingly, the two xenograft models (315T and 50T) that
exhibited a partial response to combination therapy were noted
to have higher levels of pAKT than the highly responsive 23T
xenograft (Figure 1C). We therefore explored the possibility
that the phosphatidylinositol 3-kinase (PI3K)/AKT/ mammalian
target of rapamycin (mTOR) pathway, frequently activated in
breast cancer (Faivre et al., 2006; Polyak and Metzger Filho,
2012), may have contributed to incomplete responsiveness. It
is noteworthy that no somatic mutations were detected in
PI3KCA, AKT1, or PTEN in 23T, 315T, and 50T xenografts
but that 23T and 50T carried deleterious TP53 mutations
(Table S1). Initially, the effects of AZD8055, a PI3K/mTOR inhib-
itor, were evaluated in MCF-7 breast cancer cells: combined
treatment of ABT-737 with AZD8055 induced rapid cell death,
whereas the single agents elicited minimal response (Figure 5A).
This effect was caspase-dependent, since cell death was
inhibited by the wide spectrum-caspase inhibitor Z-VAD-FMK
(Figure S4A). The interaction between ABT-737 and AZD8055
was synergistic, even at low concentrations (Figure 5B), whereas
the interaction between tamoxifen and AZD8055 was additive
(Figure S4B), as determined by BLISS synergy scores. The inter-
action between tamoxifen and ABT-737 was also synergistic at
higher (but clinically relevant) concentrations of tamoxifen (Fig-
ure S4C). Moreover, ABT-737 induced rapid apoptosis with
other dual class I PI3K and mTOR inhibitors BEZ235 or PKI-
587, whereas rapamycin and the PI3K inhibitor LY294002 were
ineffective (Figure S4A). In order to understand the potential
mechanisms underlying this synergy, the expression levels of
BCL-2 family members were compared before and after treat-
ment with AZD8055. We found that mTOR inhibition not only
increased BCL-2 but also significantly decreased the level of
phosphorylated BAD, as previously described (Hui et al., 2005;
Muranen et al., 2012; Figure 5C).
To establish whether mTOR inhibition primed cells for death
via BCL-2, we compared the effect of the BCL-2 inhibitor ABT-
199 with or without AZD8055 (Figure 5D). Induction of apoptosis
by ABT-199 was comparable to ABT-737, suggesting that the
mTOR inhibitor-mediated increase in BCL-2 was sufficient toFigure 2. The BH3 Mimetic ABT-737 Improves Tumor Response to Tam
(A) Kaplan-Meier survival curves of mice bearing 23T (n = 6–8 per arm), 315T (n = 5
with vehicle alone, ABT-737, tamoxifen (administered by s.c. injection for 23T and
and ABT-737. Log rank (Mantel-Cox) p values are shown for combination therap
(B) Cleaved caspase-3 immunostaining following 48 hr treatment. The histogram s
represent the mean ± SEM (n = 3; two or three fields per tumor).
(C) Immunostaining of bromodeoxyuridine (BrdU) uptake in 23T tumors 48 hr afte
field. Values represent the mean ± SEM (n = 3; two or three fields per tumor). Sca
three asterisks denote p < 0.001; and four asterisks denote p < 0.0001. NS, not
See also Figure S2.
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observed in 315T primary breast tumor cells cultured as tumor
spheres (Figure 5E). In keeping with the synergy observed be-
tween ABT-737 and either PI3K/mTOR or tamoxifen, MCF-7
cells were exquisitely sensitive to ABT-737, AZD8055, and
tamoxifen (Figure 5A). Similar findings were noted in 315T pri-
mary tumor cells using either ABT-737 or ABT-199 with the
PI3K/mTOR inhibitor PKI-587 and tamoxifen (Figure 5E).
Finally, the efficacy of triplet therapy was evaluated in vivo, uti-
lizing mice carrying 315T xenograft tumors. Marked attenuation
of tumor growth was observed in mice receiving the triple
therapy compared to tamoxifen/ABT-737 therapy, and median
survival was significantly prolonged from 35 to 65 days (p =
0.004) (Figures 5F and S4D).
DISCUSSION
Endocrine therapy is central to the management of estrogen
receptor-positive breast cancer. Here, we show that concomi-
tant targeting of BCL-2 provides significant improvement in
tumor response using xenograft models of primary invasive
ER-positive breast cancer. This targeting strategy induced com-
plete pathological remission in one of the tumor models.
Remarkably, ABT-199 (highly selective for BCL-2) was as effec-
tive as ABT-737 (which targets BCL-2, BCL-XL, and BCL-W),
indicating that BCL-2 is likely to be a key therapeutic target in
luminal breast cancer. Where tumors exhibited partial resistance
to doublet therapy, additional benefit was observed by targeting
the PI3K/AKT/mTOR survival pathway, frequently activated in
breast cancer (Faivre et al., 2006; Polyak and Metzger Filho,
2012). These findings provide a strong rationale for clinical
studies directed at exploiting BH3 mimetics in combination
with endocrine therapy in BCL-2-positive ER-positive breast
cancer.
BH3 mimetics are showing considerable promise in targeting
lymphoid tumors where BCL-2 is a recognized driver of tumori-
genesis frequently activated by the hallmark t(14;18) transloca-
tion or by loss of micro-RNAs that downregulate BCL-2 protein
levels. In chronic lymphocytic leukemia, even single-agent
therapy has elicited notable responses in heavily pretreated
patients with chemorefractory disease (Roberts et al., 2012). In
breast cancer, BCL-2 is overexpressed in approximately 75%
of tumors (approaching 85% for ER-positive disease) (Dawson
et al., 2010), but its role as an oncogenic driver was not clear.
Our findings suggest that BCL-2, which can be readily assayed
by standard immunohistochemistry or RT-PCR, could serve as
a highly effective predictive marker for breast cancer response
to BH3 mimetics.oxifen in BCL-2-Expressing ER-Positive Primary Xenograft Tumors
–8 per arm), 50T (n = 5–7 per arm), and 838T (n = 6 or 7 per arm) tumors treated
slow release pellet for 315T, 50T, and 838T models), and combined tamoxifen
y versus tamoxifen alone.
hows the number of cleaved caspase-3-positive cells per 1.5 mm2 field. Values
r the treatment. Histogram shows number of BrdU-positive cells per 1.5 mm2
le bars, 50 mm. One asterisk denotes p < 0.05; two asterisks denote p < 0.005;
significant (values compared to vehicle control).
Figure 3. Tamoxifen Treatment Increases BCL-2 and Sensitizes Cells to ABT-199
(A) Western blot analysis showing BCL-2, BCL-XL, MCL-1, and BIM levels in 23T tumors from mice treated for 48 hr with vehicle, tamoxifen (Tam, 0.5 mg in oil,
s.c., daily), and/or ABT-737 (50 mg/kg, i.p., daily). Actin was used as a loading control.
(B)Western blot of BCL-2 and BIM following immunoprecipitation of BCL-2. Lysates were from 23T tumor cells treated in vitro for 24 hr in the presence or absence
of tamoxifen (10 mM) and 5 hr in the presence or absence of ABT-737 (5 mM). Lane 1, no antibody control.
(C) 23T, 315T, and 50T tumor cells were cultured for 24 hr in mammosphere media in the presence of ABT-737 (1 mM) or ABT-199 (1 mM) with or without tamoxifen
(10 mM) and viability determined as compared to no treatment (NT). Shown are the mean ± SEM of triplicates from three independent experiments. One asterisk
denotes p < 0.05 and two asterisks denote p < 0.0001.
(D) Mice bearing 23T, 315T, and 50T tumors (n = 6–8 per arm) were treated with vehicle, ABT-199, tamoxifen, combined tamoxifen, and ABT-737 or combined
tamoxifen and ABT-199 and tumor volume measured. Values represent the mean ± SEM.
See also Figure S3 and Table S2.
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in breast cancer, it is frequently overexpressed in clinically
aggressive luminal B tumors, for which tumor relapse is relativelycommon and often occurs after protracted tumor dormancy. In
particular, highly proliferative tumors that express abundant
BCL-2 carry an intermediate to high risk of relapse (Abdel-FatahCancer Cell 24, 120–129, July 8, 2013 ª2013 Elsevier Inc. 125
Figure 4. Combination Therapy with ABT-
737 or ABT-199 Counteracts Tamoxifen-
Associated Endometrial Hyperplasia
(A) Images of uterine horns (with ovaries at superior
poles) in NOD-SCID-IL2Rgc
/ mice following
10 day treatment with vehicle, ABT-737 (50mg/kg,
i.p., daily), tamoxifen (0.5 mg in oil, s.c., daily), or
ABT-737 and tamoxifen. Tissue from ABT-737-
treated animals shows a slight yellow tinge. Scale
bar, 1 cm.
(B) Hematoxylin and eosin staining of transverse
sections of the miduterine horn following 10 days
of treatment. Scale bar, 500 mm.
(C) Histogram showing mean endometrial diam-
eter (±SEM)measured perpendicular to the uterine
ligament. (n = 6 mice per group; three or four
sections per animal). The size and morphology of
the myometrium and serosal layer were not
altered. The asterisk denotes p < 0.0001.
(D) Cleaved caspase-3 immunostaining of uterine
sections. Arrows show apoptotic cells shed into
the endometrial lumina following combined treat-
ment. Scale bar, 100 mm.
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subset of patients could potentially benefit from combination
therapy with tamoxifen and a BH3mimetic. Furthermore, delete-
rious p53 mutations are observed in approximately one-third of
luminal B tumors (Calza et al., 2006; Cancer Genome Atlas
Network, 2012). The response to combination therapy in the
luminal B models that carried p53 mutations (23T and 50T) is
consistent with BH3 mimetics acting downstream of p53 (Cory
et al., 2003).
It was not possible to test aromatase inhibitors in these xeno-
graft models, due to their dependence on implanted estradiol
pellets, which are necessary to recapitulate human estradiol
levels. Aromatase inhibitors generally form an integral compo-
nent of adjuvant therapy for postmenopausal women with ER-
positive breast cancer, either as primary therapy or as sequential
treatment after tamoxifen (Burstein et al., 2010). It will therefore
be important to determine whether combination BH3 mimetic
and aromatase inhibitor therapy might similarly augment tumor
response, perhaps best evaluated in the clinic. Regardless, we
speculate that it might prove possible to incorporate BH3
mimetics with tamoxifen in sequential therapy with aromatase
inhibitors or for the treatment of metastatic disease. Notably,
this would also be the case for pre- and perimenopausal women,
where tamoxifen remains the current standard for ER-positive
disease.
Our preclinical models suggest that ABT-199 could be as
potent as navitoclax (ABT-263, an oral analog of ABT-737) in
inducing a tumor response but without the thrombocytopenia
elicited by navitoclax. This observation parallels recent findings
on ABT-199 responsiveness from mouse models of leukemia
and the clinic (Souers et al., 2013; Vandenberg and Cory,
2013). Importantly, BH3 mimetic therapy appeared to be well
tolerated, as body weight and hematopoietic parameters were126 Cancer Cell 24, 120–129, July 8, 2013 ª2013 Elsevier Inc.maintained. Notably, the endometrial hy-
perplasia observed with tamoxifen was
attenuated by the BH3 mimetic. Whilethis effect may be mediated primarily through BCL-2, ABT-737
alone reduced endometrial thickness, whereas ABT-199 did
not, suggesting some involvement of BCL-XL or BCL-W. We
therefore speculate that BH3 mimetics might diminish the risk
of tamoxifen-associated endometrial hyperplasia or cancer.
Similarly, investigation of BH3 mimetics for conditions such as
endometriosis may be warranted, since the ectopic growth
and aberrant survival of endometrial tissue appears to be
strongly influenced by estrogen and prosurvival proteins that
include BCL-2 (Nasu et al., 2011).
In contrast to lymphoid malignancies where BCL-2 is a key
oncogenic driver, BH3 mimetic therapy alone was ineffective
for breast tumors. It seems likely that the response to a BCL-2
inhibitor in breast cancer may require mitochondrial upregulation
of BCL-2 complexes through concomitant exposure to other
agents, such as tamoxifen and mTOR inhibitors (as reported
here), or chemotherapy (Oakes et al., 2012). The upregulation
of BCL-2 by tamoxifen or PI3K/mTOR inhibitors has been noted
in breast cancer cells (Lam et al., 2009; Muranen et al., 2012),
and is presumably accompanied by increased binding to BH3
partner proteins, such as BIM (Me´rino et al., 2012). Similarly,
we found that dual PI3K/mTOR inhibitors triggered a decrease
in the level of phosphorylated BAD, known to result in an
increase in activated BAD (Datta et al., 1997). Together, these
agents likely prime breast tumor cells with BCL-2 complexes
that increase their sensitivity to BH3 mimetics (Certo et al.,
2006; Me´rino et al., 2012). The BH3 mimetic and PI3K/mTOR
combination may be particularly beneficial for tumors with high
BCL-2 and AKT levels, since activated AKT is associated with
resistance to tamoxifen-induced apoptosis (Campbell et al.,
2001) and predicts a worse outcome among endocrine
therapy-treated patients (Pe´rez-Tenorio et al., 2002). Although
pAKT alone is unlikely to account for the partial response
Figure 5. ABT-737 or ABT-199 Synergizes with mTOR Inhibitors to Induce Apoptosis
(A) MCF-7 cells were treated with tamoxifen (10 mM), ABT-737 (1 mM), and/or AZD8055 (1 mM) for 24 hr and then subjected to toxicity assays using phospha-
tidylinositol (PI) staining.
(B) MCF-7 cells were treated with increasing concentrations of AZD8055 and ABT-737 for 24 hr and then subjected to toxicity assays using Cell Titer Glo followed
by BLISS score analysis. BLISS synergy values are >0 on the vertical z axis.
(C) Western blot analysis of lysates from MCF-7 cells treated with 1 mM of ABT-737 or AZD8055. Actin served as a loading control.
(D) MCF-7 cells were treated with ABT-737 or ABT-199 (1 mM) and/or AZD8055 (1 mM) for 24 hr prior to performing toxicity assays using PI staining.
(E) 315T cells were treated for 24 hr with the drug combinations as indicated (n = 3). BH3 mimetics (ABT-737 and ABT-199) and PI3K/mTOR inhibitors (PKI-587,
AZD8055, and BEZ235) were applied at 1 mM. For (A), (D), and (E), the mean ± SEM is shown for three independent experiments.
(F) Kaplan-Meier survival curve of mice bearing 315T tumors (n = 7 or 8 per arm) treated with vehicle, PKI-587, tamoxifen + ABT-737, and tamoxifen + ABT-737 +
PKI-587. Log rank (Mantel-Cox) p value is shown for triple therapy versus tamoxifen + ABT-737.
See also Figure S4.
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important driver of tumor growth in these models. Compatible
with these findings, inhibition of both PI3K/mTOR and BCL-2
has been shown to increase sensitivity of matrix-attached breast
cancer cells to apoptosis (Muranen et al., 2012).
In conclusion, our findings indicate that ABT-199, the most
recent member of the BH3 mimetic family, can be harnessed to
treat solid tumors in combination therapy. It is also noteworthy
that targeting of two key survival pathways, BCL-2 and PI3K/
AKT/mTOR, appeared to be safe and effective in our human-in-
mice tumor xenograft models. These data reinforce the concept
that ABT-199 could help to refine assays ofmitochondrial priming
in tumor samples, with the goal of optimizing patient therapy (Da-
vids andLetai, 2013).While further studieswill be required todeci-
pher strategies deployed by tumors to develop resistance to
doublet and triplet therapy, our findings support the development
of BH3 mimetic therapy in breast cancer.EXPERIMENTAL PROCEDURES
Detailed experimental information and reagents used in this study is provided
in the Supplemental Experimental Procedures.
Human Tissue Samples and Mice
Human breast cancer tissues were obtained from consenting patients through
the Royal Melbourne Hospital Tissue Bank and the Victorian Cancer Biobank
with relevant institutional review board approval. Human Ethics approval was
obtained from the Walter and Eliza Hall Institute (WEHI) Human Research
Ethics Committee. NOD-SCID-IL2Rgc
/ mice were bred and maintained
according to institutional guidelines. All animal experiments were approved
by the WEHI Animal Ethics Committee.
Human Xenograft Establishment
Mice were anesthetized with ketamine/xylazine (200 mg/kg)/(20 mg/kg) intra-
peritoneal (i.p.), and analgesia was administered with carprofen (5 mg/kg) sub-
cutaneously (s.c.). Human breast tumor fragments collected between January
2008 and December 2011 were inserted into the inguinal mammary fat pads ofCancer Cell 24, 120–129, July 8, 2013 ª2013 Elsevier Inc. 127
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BCL-2 Inhibition in Breast Cancer3- or 4-week-old NOD-SCID-IL2Rgc
/ female mice. Silastic estrogen pellets
(0.5 mg) were prepared as previously described (Laidlaw et al., 1995) and im-
planted subcutaneously at the time of surgery. Following engraftment, tumors
were minced and digested in 150 U/ml collagenase (Sigma) and 50 U/ml hyal-
uronidase (Sigma) for 1 or 2 hr at 37C. The resulting organoid suspension was
sequentially digested with 0.25% trypsin 1 mM EGTA and 5 mg/ml dispase
(Roche Diagnostics) for 1 min at 37C. A single cell suspension was obtained
by filtration (40 mm), and red blood cells were removed by lysis. Cell suspen-
sion was frozen in 50% serum, 44% culture media, and 6% DMSO.
Tumor Monitoring
Cohorts of 36–42 female mice were seeded with thawed single cell suspen-
sions of early passage human breast tumors (passage 2 or 3). Briefly,
150,000–250,000 cells were resuspended in 10 ml of transplantation buffer
(50% fetal calf serum, 0.04% trypan blue in PBS and Matrigel [BD] at a ratio
of 3:1), and injected into the cleared mammary fat pads of 3- or 4-week-old
NOD-SCID-IL2Rgc
/ female mice. Mice were monitored for tumor devel-
opment three times weekly and tumor size measured using electronic vernier
calipers. Tumor volume was estimated by measuring the minimum and
maximum tumor diameters using the formula: (minimum diameter)2(maximum
diameter)/2. Once tumors arose, mice were randomized into treatment arms.
Treatment was initiated when the tumor volume reached 80–120 mm3. Mice
were sacrificed when the tumor volume exceeded 600 mm3 or animal health
deteriorated. Tumor fragments were archived in neutral buffered formalin
and also snap frozen for further analysis. Hemoglobin, white blood cell, neutro-
phil, and platelet numbers were determined by the Advia 2120 blood analysis
machine (Siemens).
Drug Administration
ABT-737 (50 mg/kg) or its vehicle was injected i.p. daily for 10 days. ABT-737
(10 mg/ml) was dissolved in DMSO (1/10 final volume) and the final volume
obtained by addition of 5% glucose solution, pH 1: propylene glycol: Tween
80 (13:6:1) to pH 4.0. ABT-199 (50 mg/kg) or its vehicle was administrated
by oral gavage for 10 days in total (two cycles of 5 days separated by a
2 day break). ABT-199 (5 mg/ml) was prepared in Phosal-50G:polyethylene
glycol-400:ethanol (6:3:1) by initially dissolving the powder in ethanol. Tamox-
ifen pellets (35 mg, 60 day release, Scientific Innovation of America) were
inserted s.c. at the commencement of treatment. For experiments where
tamoxifen was injected s.c., tamoxifen (5 mg/ml final) was dissolved in 1/10
volume of ethanol before adding 9/10 peanut oil; animals were injected with
0.5 mg. PKI-587 (3 mg/ml) was prepared in DMSO: 5% dextrose pH 3.5
(1:9) by initially dissolving the powder in DMSO. PKI-587 (15 mg/kg) or its
vehicle was injected intravenously through the tail vein once weekly,
commencing 48 hr after the first ABT-737/tamoxifen administration. The doses
of ABT-737 and ABT199 were similar to that used by Oltersdorf et al. (2005)
and Souers et al. (2013), respectively.
Statistical Analyses
Statistical analyses were performed in the GraphPad Prism software version
5.0a. Kaplan-Meier (log rank test) was used for testing significant survival of
mice related to the ethical end point for tumor size. Unpaired t tests were
used to test the significance of column means between treatments.
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the expression microar-
ray data reported in this paper is GSE47369.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.06.002.
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